| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Access versus evidence: The regulators’ dilemma
|
Schilsky, Richard L
|
|
2018
|
15 |
3 |
p. 240-242
|
article
|
| 2 |
A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes
|
Yang, Song
|
|
2018
|
15 |
3 |
p. 305-312
|
article
|
| 3 |
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST)
|
Nigrovic, Peter A
|
|
2018
|
15 |
3 |
p. 268-277
|
article
|
| 4 |
Beyond total treatment effects in randomised controlled trials: Baseline measurement of intermediate outcomes needed to reduce confounding in mediation investigations
|
Landau, Sabine
|
|
2018
|
15 |
3 |
p. 247-256
|
article
|
| 5 |
Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full
|
Califf, Robert M
|
|
2018
|
15 |
3 |
p. 235-239
|
article
|
| 6 |
Expedited approval programs at the Food and Drug Administration
|
Begg, Colin B
|
|
2018
|
15 |
3 |
p. 217-218
|
article
|
| 7 |
Expediting drug development for serious illness: Trade-offs between patient access and certainty
|
Woodcock, Janet
|
|
2018
|
15 |
3 |
p. 230-234
|
article
|
| 8 |
Increasing the use of mobile technology–derived endpoints in clinical trials
|
Herrington, William G
|
|
2018
|
15 |
3 |
p. 313-315
|
article
|
| 9 |
LIBERTI: A SMART study in plastic surgery
|
Hibbard, Jonathan C
|
|
2018
|
15 |
3 |
p. 286-293
|
article
|
| 10 |
Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review
|
Yelland, Lisa N
|
|
2018
|
15 |
3 |
p. 278-285
|
article
|
| 11 |
Reporting non-adherence in cluster randomised trials: A systematic review
|
Agbla, Schadrac C
|
|
2018
|
15 |
3 |
p. 294-304
|
article
|
| 12 |
The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme
|
Favier, Romain
|
|
2018
|
15 |
3 |
p. 257-267
|
article
|
| 13 |
The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
|
Wallach, Joshua D
|
|
2018
|
15 |
3 |
p. 243-246
|
article
|
| 14 |
The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements
|
Wallach, Joshua D
|
|
2018
|
15 |
3 |
p. 219-229
|
article
|
Journal description